Compare ACR & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACR | BNR |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | China |
| Employees | 4 | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.1M | 119.2M |
| IPO Year | N/A | 2019 |
| Metric | ACR | BNR |
|---|---|---|
| Price | $17.62 | $9.60 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $24.50 | N/A |
| AVG Volume (30 Days) | ★ 42.5K | 23.0K |
| Earning Date | 04-30-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.61 | $4.75 |
| 52 Week High | $24.61 | $41.72 |
| Indicator | ACR | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 49.22 |
| Support Level | $17.34 | $8.00 |
| Resistance Level | $19.64 | $13.39 |
| Average True Range (ATR) | 0.46 | 0.95 |
| MACD | 0.10 | 0.19 |
| Stochastic Oscillator | 57.89 | 40.37 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.